http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-027614-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae95e7759e7ecd9a4ab7f46795c1ce3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00 |
| filingDate | 2001-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-027614-A2 |
| titleOfInvention | L-NUCLEOSIDE PURINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION |
| abstract | A purine compound L-nucleoside that responds to formulas (1) to (4) that exhibit immuno-modulatory activity, especially that modulate the activity of Th1 and Th2. A pharmaceutical composition comprising a compound such as those described or a pharmaceutically acceptable ester or salt thereof, mixed with at least one pharmaceutically acceptable carrier. Use of the purine compound L-nucleoside to prepare a pharmaceutical composition of application in a method of treating a patient suffering from a medical condition which does not respond positively to the administration of said compound and comprising the steps of: provision of the compound; administration of a dose of the compound to the patient; and observation of the patient to verify the effectiveness and appearance of side effects. |
| priorityDate | 2001-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1044 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410062813 |
Total number of triples: 13.